Enfusion, Inc. (NYSE:ENFN) Given Consensus Recommendation of “Reduce” by Brokerages

Enfusion, Inc. (NYSE:ENFN) has earned an average recommendation of “Reduce” from the six analysts that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation, one has given a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $10.25.

Several analysts have issued reports on the stock. Stifel Nicolaus raised their price target on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Piper Sandler lifted their target price on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday, December 23rd.

Insider Buying and Selling

In related news, CEO Oleg Movchan sold 2,771 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total transaction of $28,070.23. Following the completion of the sale, the chief executive officer now directly owns 526,702 shares of the company’s stock, valued at $5,335,491.26. This trade represents a 0.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Neal Pawar sold 21,801 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $10.03, for a total value of $218,664.03. Following the completion of the transaction, the chief operating officer now directly owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. This represents a 1.87 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 56,404 shares of company stock valued at $580,130 over the last quarter. Corporate insiders own 36.44% of the company’s stock.

Institutional Investors Weigh In On Enfusion

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ENFN. JPMorgan Chase & Co. raised its holdings in Enfusion by 612.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company’s stock worth $1,974,000 after purchasing an additional 178,821 shares during the last quarter. Barclays PLC increased its stake in Enfusion by 251.4% in the third quarter. Barclays PLC now owns 86,039 shares of the company’s stock valued at $817,000 after purchasing an additional 61,554 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Enfusion by 7.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,029,366 shares of the company’s stock valued at $9,770,000 after buying an additional 70,367 shares during the period. Wellington Management Group LLP lifted its holdings in Enfusion by 6.7% during the third quarter. Wellington Management Group LLP now owns 976,296 shares of the company’s stock worth $9,265,000 after acquiring an additional 61,032 shares in the last quarter. Finally, TenCore Partners LP bought a new position in shares of Enfusion during the 3rd quarter valued at about $3,938,000. Institutional investors and hedge funds own 81.05% of the company’s stock.

Enfusion Trading Down 3.1 %

NYSE:ENFN opened at $9.97 on Friday. The firm has a market capitalization of $1.28 billion, a PE ratio of 249.31, a PEG ratio of 3.98 and a beta of 0.95. Enfusion has a 1 year low of $7.52 and a 1 year high of $11.38. The firm’s fifty day simple moving average is $10.11 and its 200 day simple moving average is $9.20.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.